Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Income (Loss) from Continuing Operations, Per Basic Share

2.8 / 5 stars · 68/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Income (Loss) from Continuing Operations, Per Basic Share

EMERGENT BIOSOLUTIONS INC. (EBS) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.07 per share for the 3-month period ending 2018-12-31, per its 10-K filed 2019-02-22.

Discontinued › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2019-02-22

  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for the quarter ending 2018-12-31 was -$0.07, a 109.09% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for the quarter ending 2018-09-30 was $0.42, a 48.15% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for the quarter ending 2018-06-30 was $1.00, a 809.09% increase year-over-year.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for the quarter ending 2018-03-31 was -$0.10, a 138.46% decline year-over-year.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for fiscal 2018 was $1.25, a 36.87% decline from fiscal 2017.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for fiscal 2017 was $1.98, a 26.92% increase from fiscal 2016.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for fiscal 2016 was $1.56, a 34.18% decline from fiscal 2015.
  • EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per basic share for fiscal 2015 was $2.37, a 63.45% increase from fiscal 2014.
Period endIncome (Loss) from Continuing Operations, Per Basic Share 3 monthIncome (Loss) from Continuing Operations, Per Basic Share 6 monthIncome (Loss) from Continuing Operations, Per Basic Share 9 monthIncome (Loss) from Continuing Operations, Per Basic Share 12 month
2018-12-31-$0.07
10-K · filed 2019-02-22
$1.25
10-K · filed 2019-02-22
2018-09-30$0.42
10-K · filed 2019-02-22
2018-06-30$1.00
10-K · filed 2019-02-22
2018-03-31-$0.10
10-K · filed 2019-02-22
2017-12-31$0.77
10-K · filed 2019-02-22
$1.98
10-K · filed 2019-02-22
2017-09-30$0.81
10-K · filed 2019-02-22
$1.19
10-Q · filed 2017-11-03
2017-06-30$0.11
10-K · filed 2019-02-22
$0.37
10-Q · filed 2017-08-04
2017-03-31$0.26
10-K · filed 2019-02-22
2016-12-31$0.80
10-K · filed 2018-02-23
$1.56
10-K · filed 2019-02-22
2016-09-30$0.50
10-K · filed 2018-02-23
$0.75
10-Q · filed 2017-11-03
2016-06-30-$0.05
10-K · filed 2018-02-23
$0.25
10-Q · filed 2017-08-04
2016-03-31$0.30
10-K · filed 2018-02-23
2015-12-31$1.08
10-K · filed 2017-02-28
$2.37
10-K · filed 2018-02-23
2015-09-30$1.08
10-K · filed 2017-02-28
$1.28
10-Q · filed 2016-11-09
2015-06-30$0.59
10-K · filed 2017-02-28
2015-03-31-$0.42
10-K · filed 2017-02-28
2014-12-31$1.45
10-K · filed 2017-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45